Literature DB >> 19635832

Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features.

Shonit Punwani1, Manuel Rodriguez-Justo, Alan Bainbridge, Rebecca Greenhalgh, Enrico De Vita, Stuart Bloom, Richard Cohen, Alastair Windsor, Austin Obichere, Anika Hansmann, Marco Novelli, Steve Halligan, Stuart A Taylor.   

Abstract

PURPOSE: To validate proposed magnetic resonance (MR) imaging features of Crohn disease activity against a histopathologic reference.
MATERIALS AND METHODS: Ethical permission was given by the University College London hospital ethics committee, and informed written consent was obtained from all participants. Preoperative MR imaging was performed in 18 consecutive patients with Crohn disease undergoing elective small-bowel resection. The Harvey-Bradshaw index, the C-reactive protein level, and disease chronicity were recorded. The resected bowel was retrospectively identified at preoperative MR imaging, and wall thickness, mural and lymph node/cerebrospinal fluid (CSF) signal intensity ratios on T2-weighted fat-saturated images, gadolinium-based contrast material uptake, enhancement pattern, and mesenteric signal intensity on T2-weighted fat-saturated images were recorded. Precise histologic matching was achieved by imaging the ex vivo surgical specimens. Histopathologic grading of acute inflammation with the acute inflammatory score (AIS) (on the basis of mucosal ulceration, edema, and quantity and depth of neutrophilic infiltration) and the degree of fibrostenosis was performed at each site, and results were compared with MR imaging features. Data were analyzed by using linear regression with robust standard errors of the estimate.
RESULTS: AIS was positively correlated with mural thickness and mural/CSF signal intensity ratio on T2-weighted fat-saturated images (P < .001 and P = .003, respectively) but not with mural enhancement at 30 and 70 seconds (P = .50 and P = .73, respectively). AIS was higher with layered mural enhancement (P < .001), a pattern also commonly associated with coexisting fibrostenosis (75%). Mural/CSF signal intensity ratio on T2-weighted fat-saturated images was higher in histologically edematous bowel than in nonedematous bowel (P = .04). There was no correlation between any lymph node characteristic and AIS.
CONCLUSION: Increasing mural thickness, high mural signal intensity on T2-weighted fat-saturated images, and a layered pattern of enhancement reflect histologic features of acute small-bowel inflammation in Crohn disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635832     DOI: 10.1148/radiol.2523082167

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  59 in total

1.  Quantified terminal ileal motility during MR enterography as a potential biomarker of Crohn's disease activity: a preliminary study.

Authors:  Alex Menys; David Atkinson; Freddy Odille; Asia Ahmed; Marco Novelli; Manuel Rodriguez-Justo; Ian Proctor; Shonit Punwani; Steve Halligan; Stuart A Taylor
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

2.  Magnetic resonance colonography in severe attacks of ulcerative colitis.

Authors:  C Savoye-Collet; J B Roset; E Koning; C Charpentier; S Hommel; E Lerebours; J N Dacher; G Savoye
Journal:  Eur Radiol       Date:  2012-04-27       Impact factor: 5.315

3.  Comparison of 3% sorbitol vs psyllium fibre as oral contrast agents in MR enterography.

Authors:  Sidharth Saini; Errol Colak; Shalini Anthwal; Paraskevi A Vlachou; Antony Raikhlin; Anish Kirpalani
Journal:  Br J Radiol       Date:  2014-07-25       Impact factor: 3.039

4.  Quantitative MRI of colonic mural enhancement: segmental differences exist in endoscopically proven normal colon.

Authors:  S Punwani; R Hafeez; A Bainbridge; P Boulos; S Halligan; S Bloom; S A Taylor
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

Review 5.  Chronic inflammatory diseases of the bowel: diagnosis and follow-up.

Authors:  Guillaume Gorincour; Audrey Aschero; Catherine Desvignes; François Portier; Brigitte Bourlière-Najean; Alix Ruocco-Angari; Philippe Devred; Nathalie Colavolpe; Bertrand Roquelaure; Arnaud Delarue; Philippe Petit
Journal:  Pediatr Radiol       Date:  2010-04-30

6.  Training readers to improve their accuracy in grading Crohn's disease activity on MRI.

Authors:  Jeroen A W Tielbeek; Shandra Bipat; Thierry N Boellaard; C Yung Nio; Jaap Stoker
Journal:  Eur Radiol       Date:  2014-02-22       Impact factor: 5.315

7.  Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging.

Authors:  Jordi Rimola; Núria Planell; Sonia Rodríguez; Salvadora Delgado; Ingrid Ordás; Anna Ramírez-Morros; Carmen Ayuso; Montse Aceituno; Elena Ricart; Aranzazu Jauregui-Amezaga; Julián Panés; Míriam Cuatrecasas
Journal:  Am J Gastroenterol       Date:  2015-01-27       Impact factor: 10.864

8.  Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review.

Authors:  Ilyssa O Gordon; Dominik Bettenworth; Arne Bokemeyer; Amitabh Srivastava; Christophe Rosty; Gert de Hertogh; Marie E Robert; Mark A Valasek; Ren Mao; Satya Kurada; Noam Harpaz; Paula Borralho; Reetesh K Pai; Rish K Pai; Robert Odze; Roger Feakins; Claire E Parker; Tran Nguyen; Vipul Jairath; Mark E Baker; David H Bruining; J G Fletcher; Brian G Feagan; Florian Rieder
Journal:  Gastroenterology       Date:  2019-08-30       Impact factor: 22.682

9.  PET/MR Versus PET/CT Imaging: Impact on the Clinical Management of Small-Bowel Crohn's Disease.

Authors:  Gianluca Pellino; Emanuele Nicolai; Onofrio A Catalano; Severo Campione; Francesco P D'Armiento; Marco Salvatore; Alberto Cuocolo; Francesco Selvaggi
Journal:  J Crohns Colitis       Date:  2015-11-15       Impact factor: 9.071

10.  Assessment of activity of Crohn's disease of the ileum and large bowel: proposal for a new multiparameter MR enterography score.

Authors:  L Macarini; L P Stoppino; A Centola; S Muscarella; F Fortunato; F Coppolino; N Della Valle; V Ierardi; P Milillo; R Vinci
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.